Narciclasine

Research use only, not for human use.

Narciclasine, a natural product, modulates the Rho/Rho-kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity.

Narciclasine, a natural product, modulates the Rho/Rho-kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity.(In Vitro):Narciclasine activates Rho and stress fibers in glioblastoma multiforme cells (mean IC50: ~50 nM on the 6 human glioblastoma multiforme). The mean IC50 value of 47 nM for Narciclasine across a panel of 60 cancer cell lines . The IC50 measured for radicle growth inhibition is 0.1 μM for Narciclasine .(In Vivo):The i.v. regimen of Narciclasine at 1 mg/kg significantly increases the survival of GL19 glioblastoma multiforme-bearing mice. Narciclasine when given orally at the same dose five times a week for 5 consecutive weeks also significantly increases animal survival in this model. Oral treatment with Narciclasine at 1 mg/kg significantly increases the survival of Hs683 glioblastoma multiforme-bearing mice. Increasing the number of doses administered per week does not increase the survival of these Hs683 glioblastoma multiforme-bearing mice.

Narciclasine activates Rho and stress fibers in glioblastoma multiforme cells. The mean IC50 of ~50 nM calculated on the 6 human glioblastoma multiforme (U373, Hs683, GL19, GL5, GL16, GL17), The mean IC50 value of 47 nM for Narciclasine across a panel of 60 cancer cell lines. Bioassay-guided fractionation of the A. belladonna extract resulted in the identification of lycorine as the bio-active compound. The IC50 measured for radicle growth inhibition is 0.1 μM for Narciclasine.

The i.v. regimen of Narciclasine at 1 mg/kg significantly (P=0.02) increases the survival of GL19 glioblastoma multiforme-bearing mice. Narciclasine when given orally at the same dose five times a week for 5 consecutive weeks also significantly increases animal survival in this model (P=0.008). Oral treatment with Narciclasine at 1 mg/kg significantly increases the survival (P=0.004) of Hs683 glioblastoma multiforme-bearing mice. Increasing the number of doses administered per week does not increase the survival of these Hs683 glioblastoma multiforme-bearing mice. Narciclasine appears to show similar increased survival in these models to temozolomide but at appreciable lower doses and following both oral and i.v. administration.

Lycoricidinol

Cell Cycle/DNA Damage

ROCK

ROCK

——

——

29477-83-6

307.258

C14H13NO7

>98% (HPLC)

In Vitro:?DMSO : ≥ 26 mg/mL (84.62 mM)

OC1C=C2C(NC(=O)c3c(O)c4OCOc4cc23)C(O)C1O

——

(-20℃)

With Ice Pack

≥ 2 years